Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection.
Journal
The western journal of emergency medicine
ISSN: 1936-9018
Titre abrégé: West J Emerg Med
Pays: United States
ID NLM: 101476450
Informations de publication
Date de publication:
10 Jul 2020
10 Jul 2020
Historique:
received:
08
12
2019
accepted:
05
05
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
15
12
2020
Statut:
epublish
Résumé
A small percentage of patients with skin infections later develop necrotizing fasciitis (NF). Diagnostic testing is needed to identify patients with skin infections at low risk of NF who could be discharged from the emergency department (ED) after antibiotic initiation. Elevated lactate has been associated with NF; existing estimates of the frequency of NF are based on retrospective reviews, and cases often lack testing for lactate. We present the incidence of patients with skin infections who developed NF and their baseline lactates. In four phase-3 trials, 2883 adults with complicated or acute bacterial skin and skin structure infections were randomized to dalbavancin or comparator, with early and late follow-up visits through Day 28. We prospectively collected baseline plasma lactates in one trial to assess an association with NF. NF was diagnosed in 3/2883 patients (0.1%); all three survived. In the study with prospectively collected baseline lactates (n = 622), 15/622 (2.4%) had a lactate ≥4 millimoles per liter (mmol/L), including 3/622 (0.5%) with a lactate ≥7 mmol/L. NF was not seen in patients with a lactate <4 mmol/L; NF was seen in 1/15 (6.7%) with a lactate ≥4 mmol/L, including 1/3 (33.3%) with lactate ≥7 mmol/L. NF incidence within 72 hours of antibiotic initiation in patients with complicated or acute bacterial skin and skin structure infections was extremely low (0.1%) and occurred in 6.7% with a lactate ≥4 mmol/L. Lactate <4 mmol/L can be used to identify patients at low risk of NF who could be safely discharged from the ED after antibiotic initiation.
Identifiants
pubmed: 32726268
pii: westjem.2020.5.46046
doi: 10.5811/westjem.2020.5.46046
pmc: PMC7390563
doi:
Substances chimiques
Anti-Bacterial Agents
0
Lactic Acid
33X04XA5AT
Teicoplanin
61036-62-2
dalbavancin
808UI9MS5K
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
943-948Références
Arch Surg. 2007 Sep;142(9):840-6; discussion 844-6
pubmed: 17875838
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Clin Infect Dis. 2007 Mar 1;44(5):705-10
pubmed: 17278065
J Plast Reconstr Aesthet Surg. 2015 Mar;68(3):304-11
pubmed: 25444278
J Plast Reconstr Aesthet Surg. 2013 Dec;66(12):1712-6
pubmed: 23911720
N Engl J Med. 2014 Jun 5;370(23):2169-79
pubmed: 24897082
Intensive Care Med. 2007 Jun;33(6):970-7
pubmed: 17431582
Crit Care Med. 2004 Jul;32(7):1535-41
pubmed: 15241098
N Engl J Med. 2017 Dec 7;377(23):2253-2265
pubmed: 29211672
Clin Infect Dis. 2016 Mar 1;62(5):545-51
pubmed: 26611777
J Glob Antimicrob Resist. 2019 Jun;17:60-65
pubmed: 30797084
Stat Med. 2007 May 10;26(10):2170-83
pubmed: 16927452
Clin Infect Dis. 2005 Nov 15;41(10):1407-15
pubmed: 16231250